Cencora stock costs EUR 285.20 with USD 62.2 billion market cap

Published on 10/08/2026 at 20:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora stock stood at EUR 285.20 on October 8, 2026 after EUR 283.35, plus 0.7 percent. Market cap was USD 62.2 billion, P/E 23.8.

Key points in brief

Cencora stock was at EUR 285.20 at Lang & Schwarz on October 8, 2026, plus 0.7 percent versus the prior close.
The company had a USD 62.2 billion market capitalization and a P/E ratio of 23.8 as of October 8, 2026.
Leerink Partners raised its Cencora price target from USD 380.00 to USD 388.00 on October 7, 2026.
Cencora is scheduled to report fourth-quarter fiscal 2026 results on November 4, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. (ISIN US03073E1055) was trading at EUR 285.20 at Lang & Schwarz on October 8, 2026 at 8:02 p.m. CEST, up 0.7 percent versus the prior close of EUR 283.35. The euro quotation was in after-hours trading, while the primary-market quote stood at USD 319.93 on the NYSE at 2:04 p.m. ET.

Price sits below the yearly high

The primary-market range for Cencora was USD 244.82 to USD 377.54 over the previous 52 weeks as of October 8, 2026. The latest USD 319.93 quote therefore remained below the yearly high, while the euro quotation provided the market reference for German investors.

Trading activity on the NYSE reached 348,603 shares, compared with an average volume of 1,332,498 shares as of October 8, 2026. The intraday move in the primary market was plus 0.8 percent, compared with plus 0.7 percent for the Lang & Schwarz euro quotation.

Valuation and analyst target

Cencora had a market capitalization of USD 62.2 billion and a P/E ratio of 23.8 as of October 8, 2026. The valuation comparison matters because the current P/E sits below Cardinal Health's 32.9 but close to McKesson's 24.9.

According to MarketBeat on October 7, 2026, Leerink Partners raised its Cencora price target from USD 380.00 to USD 388.00 and maintained an Outperform rating. Based on the USD 319.93 NYSE quote, that target lies 21.28 percent above the primary-market price.

Comparison with peers

Cencora Inc.: plus 0.7 percent, P/E 23.8, market capitalization USD 62.2 billion
McKesson Corporation (NYSE, USD): plus 2.3 percent, P/E 24.9, market capitalization USD 109.1 billion
Cardinal Health (NYSE, USD): plus 2.5 percent, P/E 32.9, market capitalization USD 55.7 billion

Next results date is November 4

Cencora announced on October 2, 2026 that it plans to release fourth-quarter fiscal 2026 results on November 4, 2026, before the NYSE opens. The conference call is scheduled for 8:30 a.m. ET that day.

After-hours price remains the market anchor

Cencora was trading at EUR 285.20 at Lang & Schwarz on October 8, 2026 at 8:02 p.m. CEST, plus 0.7 percent versus the prior close of EUR 283.35. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.